Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Assiut University

Status: Unknown

Conditions: Adult Acute Myeloid Leukemia

Treatments: Diagnostic Test: Cd11b and Cd56 markers

Study type: Observational

Funder types: Other

Identifiers

NCT03283228

Myeloid Leukemia Markers

Details and patient eligibility

About

1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Full description

1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Anew diagnosis cases of adult AML

Exclusion criteria

1. Pediatric AML .
2. follow up cases of adult AML

Trial design

30 participants in 2 patient groups

CD11b and CD56 markers

Description:

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Treatment:

Diagnostic Test: Cd11b and Cd56 markers

Haematological parameters in cases of adult AML

Description:

Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML

Treatment:

Diagnostic Test: Cd11b and Cd56 markers